Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.
Rostad CA, Yildirim I, Kao C, Yi J, Kamidani S, Peters E, Stephens K, Gibson T, Hsiao HM, Singh K, Spearman P, McCracken C, Agbakoba V, Tomashek KM, Goll JB, Gelber CE, Johnson RA, Lee S, Maner-Smith K, Bosinger S, Ortlund EA, Chen X, Anderson LJ, Wrammert J, Suthar M, Rouphael N, Anderson EJ. Rostad CA, et al. Among authors: kamidani s. NPJ Vaccines. 2024 Dec 23;9(1):255. doi: 10.1038/s41541-024-01042-4. NPJ Vaccines. 2024. PMID: 39715748 Free PMC article.
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Fong Y, et al. Among authors: kamidani s. Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093/cid/ciae465. Online ahead of print. Clin Infect Dis. 2024. PMID: 39325506
Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States.
Anderson EJ, Tippett A, Begier E, Gibson T, Ess G, Patel V, Taylor M, Reese O, Salazar L, Jadhao S, Sun HY, Hsiao HM, Gupta S, Li W, Stephens K, Keane A, Ciric C, Hellmeister K, Cheng A, Al-Husein Z, Bristow L, Hubler R, Liu Q, Gessner BD, Jodar L, Swerdlow D, Kalina W, Uppal S, Kamidani S, Rouphael N, Anderson LJ, Rostad CA. Anderson EJ, et al. Among authors: kamidani s. J Infect Dis. 2024 Dec 16;230(6):1342-1351. doi: 10.1093/infdis/jiae346. J Infect Dis. 2024. PMID: 38995029 Free PMC article.
Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case-Control Study.
Keane A, Tippett A, Taylor EG, Reese O, Salazar L, De Castro K, Choi C, Ciric C, Taylor M, Mitchell A, Gibson T, Puzniak L, Hubler R, Valluri SR, Wiemken TL, Lopman BA, Kamidani S, Anderson LJ, McLaughlin JM, Rostad CA, Anderson EJ. Keane A, et al. Among authors: kamidani s. Vaccines (Basel). 2024 Jun 13;12(6):657. doi: 10.3390/vaccines12060657. Vaccines (Basel). 2024. PMID: 38932386 Free PMC article.
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.
Sher LD, Boakye-Appiah JK, Hill S, Wasserman E, Xu X, Maldonado Y, Walter EB, Muñoz FM, Paulsen GC, Englund JA, Talaat KR, Barnett ED, Kamidani S, Senders S, Simões EAF, Belanger K, Parikh V, Ma H, Wang X, Lu C, Cooper D, Koury K, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Gurtman A, Kitchin N, Sabharwal C. Sher LD, et al. Among authors: kamidani s. J Pediatric Infect Dis Soc. 2024 Aug 24;13(8):421-429. doi: 10.1093/jpids/piae062. J Pediatric Infect Dis Soc. 2024. PMID: 38860591 Free PMC article. Clinical Trial.
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, Magaret CA, Robinson ST, Gilbert PB, Hyrien O, Kublin JG, Rouphael N, Falsey AR, Sobieszczyk ME, El Sahly HM, Grinsztejn B, Gray GE, Kotloff KL, Gay CL, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Huang Y, Goepfert PA, Walsh SR, Baden LR, Janes H; COVID-19 Prevention Network (CoVPN). Fisher LH, et al. JAMA Netw Open. 2024 May 1;7(5):e2412835. doi: 10.1001/jamanetworkopen.2024.12835. JAMA Netw Open. 2024. PMID: 38780941 Free PMC article.
Adverse Event Following Immunization Monitoring System in Japan.
Okuyama M, Kamiya H, Kamidani S, Saitoh A. Okuyama M, et al. Among authors: kamidani s. Pediatr Infect Dis J. 2024 Feb 1;43(2):e52-e56. doi: 10.1097/INF.0000000000004184. Epub 2023 Dec 27. Pediatr Infect Dis J. 2024. PMID: 38758206 Review.
Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.
Zambrano LD, Newhams MM, Simeone RM, Payne AB, Wu M, Orzel-Lockwood AO, Halasa NB, Calixte JM, Pannaraj PS, Mongkolrattanothai K, Boom JA, Sahni LC, Kamidani S, Chiotos K, Cameron MA, Maddux AB, Irby K, Schuster JE, Mack EH, Biggs A, Coates BM, Michelson KN, Bline KE, Nofziger RA, Crandall H, Hobbs CV, Gertz SJ, Heidemann SM, Bradford TT, Walker TC, Schwartz SP, Staat MA, Bhumbra SS, Hume JR, Kong M, Stockwell MS, Connors TJ, Cullimore ML, Flori HR, Levy ER, Cvijanovich NZ, Zinter MS, Maamari M, Bowens C, Zerr DM, Guzman-Cottrill JA, Gonzalez I, Campbell AP, Randolph AG; Overcoming COVID-19 Investigators. Zambrano LD, et al. Among authors: kamidani s. MMWR Morb Mortal Wkly Rep. 2024 Apr 18;73(15):330-338. doi: 10.15585/mmwr.mm7315a2. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38635481 Free PMC article.
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults.
Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, Lai L, Tsong R, Kao CM, Raabe V, El Sahly HM, Keitel WA, Whitaker JA, Smith MJ, Schmader KE, Swamy GK, Abate G, Winokur P, Buchanan W, Cross K, Wegel A, Xu Y, Yildirim I, Kamidani S, Rouphael N, Roberts PC, Mulligan MJ, Anderson EJ. Rostad CA, et al. Among authors: kamidani s. Clin Infect Dis. 2024 Jun 14;78(6):1757-1768. doi: 10.1093/cid/ciae173. Clin Infect Dis. 2024. PMID: 38537255 Clinical Trial.
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults.
Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD, Tippett A, Shih JWK, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer EM, Rouphael N, Anderson EJ. Kao CM, et al. Among authors: kamidani s. J Infect Dis. 2024 Nov 15;230(5):1093-1101. doi: 10.1093/infdis/jiae148. J Infect Dis. 2024. PMID: 38536442 Clinical Trial.
61 results